Promise of chemokine network-targeted nanoparticles in combination nucleic acid therapies of metastatic cancer

Ying Xie, Yazhe Wang, Jing Li, Yu Hang, David Oupicky

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Chemokines and chemokine receptors play key roles in cancer progression and metastasis. Although multiple chemokines and chemokine receptors have been investigated, inhibition of CXCR4 emerged as one of the most promising approaches in combination cancer therapy, especially when focused on the metastatic disease. Small RNA molecules, such as small interfering RNA (siRNA) and microRNA (miRNA), represent new class of therapeutics for cancer treatment through RNA interference-mediated gene silencing. However, the clinical applicability of siRNA and miRNA is severely limited by the lack of effective delivery systems. There is a significant therapeutic potential for CXCR4-targeted nanomedicines in combination with the delivery of siRNA and miRNA in cancer. Recently developed CXCR4-targeted polymeric drugs and nanomedicines, including cyclam- and chloroquine-based polymeric CXCR4 antagonists are introduced here and their ability to deliver functional siRNA and miRNA is discussed. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.

Original languageEnglish (US)
Article numbere1528
JournalWiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
Volume11
Issue number2
DOIs
StatePublished - Mar 1 2019

Fingerprint

Nucleic acids
Nanomedicine
Medical nanotechnology
RNA
MicroRNAs
Chemokines
Nanoparticles
Nucleic Acids
Small Interfering RNA
Chemokine Receptors
Neoplasms
Nanotechnology
Oncology
Systems Biology
Chloroquine
Gene Silencing
Drug Discovery
Therapeutics
RNA Interference
Genes

Keywords

  • CXCR4
  • metastatic cancer
  • miRNA
  • nanomedicine
  • polymeric drug
  • siRNA

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering

Cite this

Promise of chemokine network-targeted nanoparticles in combination nucleic acid therapies of metastatic cancer. / Xie, Ying; Wang, Yazhe; Li, Jing; Hang, Yu; Oupicky, David.

In: Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, Vol. 11, No. 2, e1528, 01.03.2019.

Research output: Contribution to journalReview article

@article{4988bae4bfaa4716bf4e4d6370ae0c03,
title = "Promise of chemokine network-targeted nanoparticles in combination nucleic acid therapies of metastatic cancer",
abstract = "Chemokines and chemokine receptors play key roles in cancer progression and metastasis. Although multiple chemokines and chemokine receptors have been investigated, inhibition of CXCR4 emerged as one of the most promising approaches in combination cancer therapy, especially when focused on the metastatic disease. Small RNA molecules, such as small interfering RNA (siRNA) and microRNA (miRNA), represent new class of therapeutics for cancer treatment through RNA interference-mediated gene silencing. However, the clinical applicability of siRNA and miRNA is severely limited by the lack of effective delivery systems. There is a significant therapeutic potential for CXCR4-targeted nanomedicines in combination with the delivery of siRNA and miRNA in cancer. Recently developed CXCR4-targeted polymeric drugs and nanomedicines, including cyclam- and chloroquine-based polymeric CXCR4 antagonists are introduced here and their ability to deliver functional siRNA and miRNA is discussed. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.",
keywords = "CXCR4, metastatic cancer, miRNA, nanomedicine, polymeric drug, siRNA",
author = "Ying Xie and Yazhe Wang and Jing Li and Yu Hang and David Oupicky",
year = "2019",
month = "3",
day = "1",
doi = "10.1002/wnan.1528",
language = "English (US)",
volume = "11",
journal = "Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology",
issn = "1939-0041",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Promise of chemokine network-targeted nanoparticles in combination nucleic acid therapies of metastatic cancer

AU - Xie, Ying

AU - Wang, Yazhe

AU - Li, Jing

AU - Hang, Yu

AU - Oupicky, David

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Chemokines and chemokine receptors play key roles in cancer progression and metastasis. Although multiple chemokines and chemokine receptors have been investigated, inhibition of CXCR4 emerged as one of the most promising approaches in combination cancer therapy, especially when focused on the metastatic disease. Small RNA molecules, such as small interfering RNA (siRNA) and microRNA (miRNA), represent new class of therapeutics for cancer treatment through RNA interference-mediated gene silencing. However, the clinical applicability of siRNA and miRNA is severely limited by the lack of effective delivery systems. There is a significant therapeutic potential for CXCR4-targeted nanomedicines in combination with the delivery of siRNA and miRNA in cancer. Recently developed CXCR4-targeted polymeric drugs and nanomedicines, including cyclam- and chloroquine-based polymeric CXCR4 antagonists are introduced here and their ability to deliver functional siRNA and miRNA is discussed. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.

AB - Chemokines and chemokine receptors play key roles in cancer progression and metastasis. Although multiple chemokines and chemokine receptors have been investigated, inhibition of CXCR4 emerged as one of the most promising approaches in combination cancer therapy, especially when focused on the metastatic disease. Small RNA molecules, such as small interfering RNA (siRNA) and microRNA (miRNA), represent new class of therapeutics for cancer treatment through RNA interference-mediated gene silencing. However, the clinical applicability of siRNA and miRNA is severely limited by the lack of effective delivery systems. There is a significant therapeutic potential for CXCR4-targeted nanomedicines in combination with the delivery of siRNA and miRNA in cancer. Recently developed CXCR4-targeted polymeric drugs and nanomedicines, including cyclam- and chloroquine-based polymeric CXCR4 antagonists are introduced here and their ability to deliver functional siRNA and miRNA is discussed. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.

KW - CXCR4

KW - metastatic cancer

KW - miRNA

KW - nanomedicine

KW - polymeric drug

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=85046011203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046011203&partnerID=8YFLogxK

U2 - 10.1002/wnan.1528

DO - 10.1002/wnan.1528

M3 - Review article

C2 - 29700990

AN - SCOPUS:85046011203

VL - 11

JO - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

JF - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

SN - 1939-0041

IS - 2

M1 - e1528

ER -